Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1894 - Genomic characterisation of locally advanced pancreatic adenocarcinoma


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site

Pancreatic Adenocarcinoma


Sarah Picardo


Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268


S. Picardo1, G.M. O'Kane1, S. Fischer2, A. Zhang3, R. Denroche3, G. Jang3, A. dodd4, R.C. Grant4, B. Gruenwald3, S. Moura4, Y. Wang5, E. Elimova6, R. Prince4, G. Zogopoulos7, F. Notta3, J. Wilson3, S. Gallinger8, J.J. Knox9

Author affiliations

  • 1 Medical Oncology, Princess Margaret Cancer Centre, M5S 1Z5 - Toronto/CA
  • 2 Pathology, Princess Margaret Cancer Centre, m5g - c/CA
  • 3 Pancurx, Ontario Institute for Cancer Research, M5g 0A3 - toronto/CA
  • 4 Medical Oncology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 5 Surgical Oncology, McGill Univeristy Health, H4A3J1 - Montreal/CA
  • 6 Medical Oncology, Princess Margaret Cancer Centre, M5G 2C1 - Toronto/CA
  • 7 Surgical Oncology, McGill University Health Centre, H4A3J1 - Montreal/CA
  • 8 Division Of Surgical Oncology, Toronto General Hospital, M5G 2C4 - Toronto/CA
  • 9 Medical Oncology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1894


Locally advanced pancreatic adenocarcinoma (LAPC) is treated similarly to metastatic pancreatic cancer (MPC). It has previously been thought that SMAD4 is wildtype (WT) in LAPC. We describe results of whole genome (WGS) and RNA sequencing (RNAseq) of LAPC and MPC tumours.


Patients with LAPC and MPC were enrolled in the COMPASS clinical trial (NCT02750657). Clinical, demographic and survival data were collected. WGS and RNAseq was performed along with modified Moffitt classification (basal-like or classical).


Patients with LAPC (n = 27) and MPC (n = 163) did not differ in terms of age, gender or smoking status. Patients with LAPC had lower BMI (p = 0.005) than those with MPC. More LAPC patients received FOLFIRINOX than those with MPC (p = 0.003). LAPC/MPC tumours had similar rates of KRAS, p53, CDKN2A and SMAD4 mutations and similar levels of ploidy, indels, neoantigens and single nucleotide variants. There was a slight increase in structural variants in MPC vs. LAPC (p = 0.05). No LAPC tumours were homologous recombination deficient (HRD) or KRAS WT, compared with 10 MPC (HRD) and 15 MPC (KRAS-WT). LAPC patients with SMAD4 mutations had higher baseline Ca19.9 than those with WT SMAD4 (p = 0.0048). All LAPC were Moffitt classical subtype on RNAseq, compared with 77% of MPC (p = 0.0049). LAPC patients had improved OS compared with MPC patients on univariate analysis (p = 0.04) but not on multivariate analysis. There was no difference in OS between LAPC and classical subtype MPC, or between LAPC patients with/without SMAD4 mutations.


Patients with LAPC have a similar molecular profile to those with MPC with similar rates of altered drivers including SMAD4. LAPC tumours are more likely to be Moffitt classical subtype and have similar OS to classical subtype MPC. LAPC patients with SMAD4 mutations had similar OS to those with WT SMAD4. These data suggest that patients with LAPC should be treated similarly to those with classical-subtype MPC.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

The authors.


Government of Ontario, Wallace McCain Centre for Pancreatic Cancer, Princess Margaret Cancer Foundation, Canadian Cancer Society Research Institute Grant (702316), Pancreatic Cancer Canada Foundation, Canadian Friends of the Hebrew University (Alex U. Soyka), Lebovic Chair in Hepatobiliary/Pancreatic Surgical Oncology.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.